tradingkey.logo

Krystal Biotech Inc

KRYS

140.020USD

-16.960-10.80%
交易中 美東報價延遲15分鐘
4.05B總市值
32.64本益比TTM

Krystal Biotech Inc

140.020

-16.960-10.80%
關於 Krystal Biotech Inc 公司
Krystal Biotech, Inc. 是一家綜合性商業階段生物技術公司。該公司專注於發現、開發和商業化基因藥物,以治療具有高度未滿足醫療需求的疾病。其處於臨牀和臨牀前開發各個階段的產品候選包括 VYJUVEK、KB407、KB408、KB707、KB105、KB104、KB104 和 KB301。其商業產品 VYJUVEK 是一種非侵入性、局部性、可重複的基因療法,旨在直接應用於 DEB 傷口時提供兩個 COL7A1 基因拷貝。VYJUVEK 旨在通過爲患者的皮膚細胞提供製造正常 COL7 蛋白的模板來在分子水平上治療 DEB,從而解決根本的致病機制。KB407 是爲治療囊性纖維化而開發的。KB408 是爲治療 Alpha-1 抗胰蛋白酶缺乏症而開發的。 KB707 是爲治療實體腫瘤而開發的。KB105 是爲治療 TGM1 缺陷型常染色體隱性先天性魚鱗病而開發的。
公司簡介
公司代碼KRYS
公司名稱Krystal Biotech Inc
上市日期Sep 20, 2017
CEOMr. Krish S. Krishnan
員工數量275
證券類型Ordinary Share
年結日Sep 20
公司地址2100 Wharton St Ste 701
城市PITTSBURGH
上市交易所NASDAQ Global Select Consolidated
國家United States of America
郵編15203
電話14125865830
網址https://www.krystalbio.com/
公司代碼KRYS
上市日期Sep 20, 2017
CEOMr. Krish S. Krishnan
公司高階主管
名稱
名稱/職務
職務
持股
持股變動
Mr. Krish S. Krishnan
Mr. Krish S. Krishnan
Chairman of the Board, President, Chief Executive Officer
Chairman of the Board, President, Chief Executive Officer
1.65M
-1.49%
Ms. Suma M. Krishnan
Ms. Suma M. Krishnan
President - Research and Development, Founder, Director
President - Research and Development, Founder, Director
1.58M
-1.56%
Mr. Dino A. Rossi
Mr. Dino A. Rossi
Independent Director
Independent Director
78.69K
--
Dr. Adm. Christopher (Chris) Mason, M.D., Ph.D.
Dr. Adm. Christopher (Chris) Mason, M.D., Ph.D.
Independent Director
Independent Director
--
--
Mr. Kirti Ganorkar
Mr. Kirti Ganorkar
Independent Director
Independent Director
--
--
Mr. Daniel S. Janney
Mr. Daniel S. Janney
Lead Independent Director
Lead Independent Director
--
--
Ms. Catherine Mazzacco
Ms. Catherine Mazzacco
Independent Director
Independent Director
--
--
Dr. Everett Rand Sutherland, M.D.
Dr. Everett Rand Sutherland, M.D.
Independent Director
Independent Director
--
--
Mr. Julian S. Gangolli
Mr. Julian S. Gangolli
Independent Director
Independent Director
--
--
Ms. Meg Dodge
Ms. Meg Dodge
Investor Relations
Investor Relations
--
--
查看更多
名稱
名稱/職務
職務
持股
持股變動
Mr. Krish S. Krishnan
Mr. Krish S. Krishnan
Chairman of the Board, President, Chief Executive Officer
Chairman of the Board, President, Chief Executive Officer
1.65M
-1.49%
Ms. Suma M. Krishnan
Ms. Suma M. Krishnan
President - Research and Development, Founder, Director
President - Research and Development, Founder, Director
1.58M
-1.56%
Mr. Dino A. Rossi
Mr. Dino A. Rossi
Independent Director
Independent Director
78.69K
--
Dr. Adm. Christopher (Chris) Mason, M.D., Ph.D.
Dr. Adm. Christopher (Chris) Mason, M.D., Ph.D.
Independent Director
Independent Director
--
--
Mr. Kirti Ganorkar
Mr. Kirti Ganorkar
Independent Director
Independent Director
--
--
Mr. Daniel S. Janney
Mr. Daniel S. Janney
Lead Independent Director
Lead Independent Director
--
--
收入明細
暫無數據
暫無數據
業務
地區
暫無數據
股東統計
更新時間: 5月20日 週二
更新時間: 5月20日 週二
持股股東
股東類型
持股股東
持股股東
佔比
Fidelity Management & Research Company LLC
14.93%
BlackRock Institutional Trust Company, N.A.
12.58%
The Vanguard Group, Inc.
9.76%
Avoro Capital Advisors LLC
9.45%
Krishnan (Krish S)
5.70%
Other
47.59%
持股股東
持股股東
佔比
Fidelity Management & Research Company LLC
14.93%
BlackRock Institutional Trust Company, N.A.
12.58%
The Vanguard Group, Inc.
9.76%
Avoro Capital Advisors LLC
9.45%
Krishnan (Krish S)
5.70%
Other
47.59%
股東類型
持股股東
佔比
Investment Advisor
60.67%
Investment Advisor/Hedge Fund
28.60%
Individual Investor
11.88%
Hedge Fund
4.71%
Private Equity
2.46%
Research Firm
1.97%
Pension Fund
1.00%
Sovereign Wealth Fund
0.79%
Bank and Trust
0.38%
機構持股
更新時間: 7月1日 週二
更新時間: 7月1日 週二
報告期間
機構數
持股數
持股佔比
持股變動
2025Q2
587
32.60M
112.80%
-1.31M
2025Q1
597
32.73M
113.26%
-1.18M
2024Q4
555
33.11M
114.98%
-1.88M
2024Q3
532
33.56M
116.82%
-1.97M
2024Q2
492
34.00M
119.08%
+2.68M
2024Q1
457
29.99M
105.21%
-815.24K
2023Q4
418
29.64M
105.24%
-696.04K
2023Q3
406
29.89M
107.26%
-297.23K
2023Q2
399
29.15M
106.30%
+625.16K
2023Q1
372
27.33M
106.10%
-304.41K
查看更多
股東持股明細
名稱
持股數
佔比
持股變動
變動比例
公告日期
Fidelity Management & Research Company LLC
4.31M
14.93%
+7.02K
+0.16%
Mar 31, 2025
BlackRock Institutional Trust Company, N.A.
3.63M
12.58%
-103.60K
-2.77%
Mar 31, 2025
The Vanguard Group, Inc.
2.82M
9.76%
-53.17K
-1.85%
Mar 31, 2025
Avoro Capital Advisors LLC
2.73M
9.45%
+102.18K
+3.89%
Mar 31, 2025
Krishnan (Krish S)
1.67M
5.79%
-25.00K
-1.47%
Mar 25, 2025
Krishnan (Suma M)
1.60M
5.55%
+25.00K
+1.58%
Mar 25, 2025
State Street Global Advisors (US)
1.23M
4.24%
-52.27K
-4.09%
Mar 31, 2025
Capital World Investors
954.47K
3.3%
+75.27K
+8.56%
Mar 31, 2025
Capital Research Global Investors
952.23K
3.3%
--
--
May 31, 2025
Redmile Group, LLC
737.67K
2.55%
-15.50K
-2.06%
Mar 31, 2025
查看更多
持股ETF
更新時間: 8月2日 週六
更新時間: 8月2日 週六
機構名稱
佔比
Franklin Genomic Advancements ETF
3.52%
ALPS Medical Breakthroughs ETF
2.67%
First Trust NYSE Arca Biotechnology Index Fund
2.62%
Invesco S&P SmallCap Health Care ETF
2.5%
Virtus LifeSci Biotech Products ETF
1.89%
SPDR S&P Biotech ETF
1.21%
Invesco S&P SmallCap 600 Pure Growth ETF
1.05%
Direxion Daily S&P Biotech Bull 3X Shares
0.69%
WisdomTree BioRevolution Fund
0.58%
Vanguard S&P Small-Cap 600 Growth Index Fund
0.51%
查看更多
Franklin Genomic Advancements ETF
佔比3.52%
ALPS Medical Breakthroughs ETF
佔比2.67%
First Trust NYSE Arca Biotechnology Index Fund
佔比2.62%
Invesco S&P SmallCap Health Care ETF
佔比2.5%
Virtus LifeSci Biotech Products ETF
佔比1.89%
SPDR S&P Biotech ETF
佔比1.21%
Invesco S&P SmallCap 600 Pure Growth ETF
佔比1.05%
Direxion Daily S&P Biotech Bull 3X Shares
佔比0.69%
WisdomTree BioRevolution Fund
佔比0.58%
Vanguard S&P Small-Cap 600 Growth Index Fund
佔比0.51%
分紅派息
近5年累計派現 0.00 美元
公告日期
分紅計劃
股權登記日
現金發放日
除權除息日
暫無數據
拆合股
公告日期
類型
比率
暫無數據
公告日期
類型
比率
暫無數據
KeyAI